Skip to contentK
Kyntra Bio, Inc.
K
KYNBKyntra Bio, Inc. Q3 2019 · 10-Q
Revenue$33.17M$33.17M+14.3% vs Q3 2018 Net Income-$49.44M-$49.44MN/M vs Q3 2018 EPS Diluted-$0.57-$0.57N/M vs Q3 2018 Operating Income-$52,854,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Kyntra Bio, Inc. · CIK 921299 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$29,294,000N/M Margins · derivedOperating margin-159.3%−12.0 pt vs Q3 2018
Net margin-149.0%−2.4 pt vs Q3 2018
ended Sep 30, 2019 · filed Nov 12, 2019 · 43 d after period end